Ranbaxy's 7 anti retrovirals included in WHO list
|
|
BY OUR PHARMA CORRESPONDENT
13th August,2005:The World Health Organization
(WHO), Geneva, has included Ranbaxy's seven anti
retrovirals (ARVs) in its pre-qualification list,
the company announced in a press release.
The products approved by WHO are:
Lamivudine 150mg+Nevirapine 200mg+Stavudine 40mg
tablets
Lamivudine 150mg+Nevirapine 200mg+Stavudine 30mg
tablets
Lamivudine 150mg+Stavudine 40mg tablets
Lamivudine 150mg+Stavudine 30mg tablets
Lamivudine 150mg+Zidovudine 300mg tablets
Lamivudine 150mg tablets, and
Zidovudine 300mg tablets
This significant development should unlock the ARV
supplies and make it easier for developing
countries to access affordable generic ARVs, and
scale up treatment rapidly. This, along with other
USFDA approvals, will ensure that HIV patients
have access to quality generic ARVs, irrespective
of the funding programme in their country, the
Ranbaxy release said.
Ranbaxy’s ARVs including the products recently
approved by WHO, are manufactured at the company’s
state-of-the-art manufacturing facilities, that
have been inspected and approved by some of the
most stringent agencies in the world, including
USFDA and WHO.
The Contract Research Organisations (CROs) used by
Ranbaxy to carry out bio-equivalence studies for
its ARVs are globally reputed and conduct and file
their studies routinely with some of the most
stringent regulatory authorities around the world.
The CROs also regularly undergo routine audits by
these regulatory authorities.
Since 2001, Ranbaxy has been providing ARV
medicines of high quality at affordable prices to
AIDS/HIV affected countries for patients who might
not otherwise be able to gain access to this
therapy. The Company's ARVs have been used as
mainstays in various large treatment programs,
both National and NGO/Institutional with good
results. Ranbaxy is committed to support this
humanitarian effort as a further means of lending
support to the global fight against HIV/AIDS.
Ranbaxy Laboratories Limited, India's largest
pharmaceutical company, manufactures and markets
brand and generic pharmaceuticals and Active
Pharmaceutical Ingredients. Ranbaxy's continued
focus on R&D has resulted in several approvals in
developed markets and significant progress in New
Drug Discovery Research. The Company is selling
its products in over 100 countries and has an
expanding international portfolio of affiliates,
joint ventures and alliances, ground operations in
44 countries and manufacturing operations in 7
countries.
BY OUR PHARMA CORRESPONDENT |
|
|
